logo-loader

Medexus Pharmaceuticals Inc

Receive alerts
Market:
TSX-V
Market Cap:
$54.73 m
Price
3.87 CAD
Change
0.00%
52 weeks high
5.08
52 weeks low
3.50

In brief

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Teamwork. Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, pediatrics, and specialty oncology. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative prescription allergy medication with a unique mode of action.

Deep dive We explore the investor case for growth companies

Snapshot

The Toronto-based company’s leading products are Rasuvo and Metoject, a unique formulation of methotrexate that is designed to treat rheumatoid arthritis and other auto-immune diseases